Estrogen receptors as therapeutic targets in breast cancer

Current Topics in Medicinal Chemistry

Volumn 6, Issue 3, 2006, Pages 181-202

  Ariazi, Eric A ^a   Ariazi, Jennifer L ^a,b   Cordera, Fernando ^a   Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Antihormonal resistance; Aromatase inhibitor; Breast cancer; Estrogen receptor; Pure antiestrogen; Selective estrogen receptor modulator

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ARZOXIFENE; BAZEDOXIFENE; COUMESTROL; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GENISTEIN; GROWTH FACTOR RECEPTOR; GW 7604; IDOXIFENE; LASOFOXIFENE; LETROZOLE; PROGESTERONE RECEPTOR; RALOXIFENE; SCH 57050; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 253; ZK 703;

ABSENCE OF SIDE EFFECTS; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CELL MEMBRANE; CELL NUCLEUS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; ENDOMETRIUM CANCER; FATIGUE; FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMMUNE DEFICIENCY; MOLECULAR INTERACTION; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; UTERUS PROLAPSE; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VOMITING; WEAKNESS;

ANIMALS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33646129245     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776173483     Document Type: Review

References (228)

1. Berry, D.A.; Cronin, K.A.; Plevritis, S.K.; Fryback, D.G.; Clarke, L.; Zelen, M.; Mandelblatt, J.S.; Yakovlev, A.Y.; Habbema, J.D.; Feuer, E.J. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 2005, 353, 1784-1792.
2. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M.J. Cancer statistics, 2005. CA Cancer J. Clin. 2005. 2005, 55, 10-30.
3. Jensen, E.V. On the mechanism of estrogen action. Perspect Biol Med. 1962, 6, 47-59.
4. Jensen, E.V.; Jordan, V.C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 2003, 9, 1980-1989.
5. Toft D.; Gorski, J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. USA 1966, 55, 1574-1581.
6. Greene, G.L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231, 1150-1154.
7. Green, S.; Walter, P.; Kumar, V.; Krust, A.; Bornert, J.M.; Argos, P.; Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320, 34-139.
8. Kuiper, G.G.; Enmark, E.; Pelto-Huikko, M.; Jason, S.; Gustafsson, J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93, 5925-5930.
9. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392, 49-53.
10. Beato, M. Gene regulation by steroid hormones. Cell 1989, 56, 335-344.
11. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
12. Truss, M.; Beato, M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr. Rev. 1993, 14, 459-479.
13. Tsai, M.J.O'Malley, B.W. Molecular mechanisms of action of steroid/ thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-486.
14. Beato, M.; Herrlich, P.; Schutz, G. Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83, 851-857.
15. Gustafsson, J.A. Estrogen receptor beta - a new dimension in estrogen mechanism of action. J. Endocrinol. 1999, 163, 379-383.
16. Pearce, S.T.; Jordan, V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol. Hematol. 2004, 50, 3-22.
17. Koehler, K.F.; Helguero, L.A.; Haldosen, L.-A.; Warner, M.; Gustafsson, J.-A. Reflections on the Discovery and Significance of Estrogen Receptor {beta}. Endocr. Rev. 2005, 26, 465-478.
18. Ariazi, E.A.; Clark, G.M.; Mertz, J.E. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res. 2002, 62, 6510-6518.
19. Leygue, E.; Dotzlaw, H.; Watson, P.H.; Murphy, L.C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 1998. 58, 3197-3201.
20. Saji, S.; Hirose, M.Toi, M. Clinical significance of estrogen receptor betain breast cancer. Cancer Chemother. Pharmacol. 2005, 56 Suppl 7, 21-26.
21. Menasce, L.P.; White, G.R.; Harrison, C.J.; Boyle, J.M. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993, 17, 263-265.
22. Kumar, V.; Green, S.; Stack, G.; Berry, M.; Jin, J.R.; Chambon, P. Functional domains of the human estrogen receptor. Cell 1987, 51, 941-951.
23. Kumar, V.; Green, S.; Staub, A.; Chambon, P. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO J. 1986, 5, 2231-2236.
24. Lees, J.A.; Fawell, S.E. Parker, Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res. 1989, 17, 5477-5488.
25. MacGregor, J.I.; Jordan, V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 1998, 50, 151-196.
26. Brzozowski, A.M.; Pike, A.C.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G.L.; Gustafsson, J.A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
27. Jordan, V.C.; Schafer, J.M.; Levenson, A.S.; Liu, H.; Pease, K.M.; Simons, L.A.; Zapf, J.W. Molecular classification of estrogens. Cancer Res. 2001, 61, 6619-6623.
28. Liu, H.; Park, W.C.; Bentrem, D.J.; McKian, K.P.; Reyes Ade, L.; Loweth, J.A.; Schafer, J.M.; Zapf, J.W.; Jordan, V.C. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J. Biol. Chem. 2002, 277, 9189-9198.
29. Liu, H.; Lee, E.S.; De Los Reyes, A.; Zapf, J.W.; Jordan, V.C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res. 2001, 61, 3632-3639.
30. Bentrem, D.; Fox, J.E.; Pearce, S.T.; Liu, H.; Pappas, S.; Kupfer, D.; Zapf, J.W.; Jordan, V.C. Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res. 2003, 63, 7490-7496.
31. Gasc, J.M.; Baulieu, E.E. Steroid hormone receptors: intracellular distribution. Biol Cell. 1986, 56, 1-6.
32. Ylikomi, T.; Wurtz, J.M.; Syvala, H.; Passinen, S.; Pekki, A.; Haverinen, M.; Blauer, M.; Tuohimaa, P.; Gronemeyer, H. Reappraisal of the role of heat shock proteins as regulators of steroid receptor activity. Crit. Rev. Biochem. Mol. Biol. 1998, 33, 437-466.
33. Sanchez, R.; Nguyen, D.; Rocha, W.; White, J.H.; Mader, S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 2002, 24, 244-254.
34. Bjornstrom, L.; Sjoberg, M. Mechanisms of Estrogen Receptor Signalling: Convergence of Genomic and Nongenomic Actions on Target Genes. Mol. Endocrinol. 2005, 19, 833-842.
35. Chen, J.D.; Li, H. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Crit. Rev. Eukaryot. Gene Expr. 1998, 8, 169-190.
36. Jenster, U. Coactivators and corepressors as mediators of nuclear receptor function: an update. Mol. Cell Endocrinol. 1998, 143, 1-7.
37. Horwitz, K.B.; Jackson, T.A.; Bain, D.L.; Richer, J.K.; Takimoto, G.S.; Tung, L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 1996, 10, 1167-1177.
38. Shang, Y.; Hu, X.; DiRenzo, J.; Lazar, M.A.; Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103, 843-852.
39. Paech, K.; Webb, P.; Kuiper, G.G.; Nilsson, S.; Gustafsson, J.; Kushner, P.J.; Scanlan, T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277, 1508-1510.
40. Uhf, R.M.; Anderson, C.M.; Webb, P.; Kushner, P.J. Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element. Endocrinology 1997, 138, 2900-2908.
41. Webb, P.; Lopez, G.N.; Uht, R.M.; Kushner, P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 1995, 9, 443-456.
42. Wang, F.; Hoivik, D.; Pollenz, R.; Safe, S. Functional and physical interactions between the estrogen receptor Sp1 and nuclear aryl hydrocarbon receptor complexes. Nucleic Acids Res. 1998, 26, 3044-3052.
43. Sun, G.; Porter, W.; Safe, S. Estrogen-induced retinoic acid receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complex. Mol. Endocrinol. 1998, 12, 882-890.
44. Porter, W.; Saville, B.; Hoivik, D.; Safe, S. Functional synergy between the trariscription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 1997, 11, 1569-1580.
45. Porter, W.; Wang, F.; Wang, W.; Duan, R.; Safe, S. Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. Mol. Endocrinol. 1996, 10, 1371-1378.
46. Krishnan, V.; Wang, X.; Safe, S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J. Biol. Chem. 1994, 269, 15912-15917.
47. Jakacka, M.; Ito, M.; Weiss, J.; Chien, P.Y.; Gehm, B.D.; Jameson, J.L. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem. 2001, 276, 13615-13621.
48. Rogatsky, I.; Trowbridge, J.M.; Garabedian, M.J. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem. 1999, 274, 22296-22302.
49. Ali, S.; Metzger, D.; Bornert, J.M.; Chambon, P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 1993, 12, 1153-1160.
50. Bunone, G.; Briand, P.A.; Miksicek, R.J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
51. Joel, P.B.; Traish, A.M.; Lannigan, D.A. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol. Endocrinol. 1995, 9, 1041-1052.
52. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; Metzger, D.; Chambon, P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science 1995, 270, 1491-1494.
53. Le Goff, P.; Montano, M.M.; Schodin, D.J.; Katzenellenbogen, B.S. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem. 1994, 269, 4458-4466.
54. Chen, D.; Washbrook, E.; Sarwar, N.; Bates, G.J.; Pace, P.E.; Thirunuvakkarasu, V.; Taylor, J.; Epstein, R.J.; Fuller-Pace, F.V.; Egly, J.M.; Coombes, R.C.; Ali, S. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002, 21, 4921-4931.
55. Arnold, S.F.; Obourn, J.D.; Jaffe, H.; Notides, A.C. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol. Endocrinol. 1994, 8, 1208-1214.
56. Campbell, R.A.; Bhat-Nakshatri, P.; Patel, N.M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001, 276, 9817-9824.
57. Joel, P.B.; Smith, J.; Sturgill, T.W.; Fisher, T.L.; Blenis, J.; Lannigan, D.A. pp90rsk1 regulates estrogen receptor-mediated transcription1 through phosphorylation of Ser-167. Mol. Cell Biol. 1998, 18, 1978-1984.
58. Sun, M.; Paciga, J.E.; Feldman, R.I.; Yuan, Z.; Coppola, D.; Lu, Y.Y.; Shelley, S.A.; Nicosia, S.V.; Cheng, -J.Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalPha) via interaction between ERalpha and P13K. Cancer Res. 2001, 61, 5985-5991.
59. Castano, E.; Vorojeikina, D.P.; Notides, A.C. Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochem. J. 1997, 326 (Pt 1), 149-157.
60. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjold, M.; Gustafsson, J.A.; Human estrogen receptor beta-gene structure, chromosomal location, and expression pattern. J. Clin. Endocrinol. Metab. 1997, 82, 4258-4265.
61. Ogawa, S.; Inoue, S.; Watanabe, T.; Hiroi, H.; Orimo, A.; Hosoi, T.; Ouchi, Y.; Muramatsu, M. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem. Biophys. Res. Commun. 1998, 243, 122-126.
62. Hall, J.M.; McDonnell, D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140, 5566-5578.
63. Elledge, R.M.; Green, S.; Pugh, R.; Allred, D.C.; Clark, G.M.; Hill, J.; Ravdin, P.; Martino, S.; Osborne, C.K. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. Int. J. Cancer (Pred. Oncol.). 2000, 89, 111-117.
64. Mann, S.; Laucirica, R.; Carlson, N.; Younes, P.S.; Ali, N.; Younes, A.; Li, Y.; Younes, M. Estrogen receptor beta expression in invasive breast cancer. Hum. Pathol. 2001, 32, 113-118.
65. Jarvinen, T.A.; Pelto-Huikko, M.; Holli, K.; Isola, J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol. 2000, 156, 29-35.
66. Omoto, Y.; Kobayashi, S.; Inoue, S.; Ogawa, S.; Toyama, T.; Yamashita, H.; Muramatsu, M.; Gustafsson, J.A.; Iwase, H. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur. J. Cancer 2002, 38, 380-386.
67. Speirs, V.; Malone, C.; Walton, D.S.; Kerin, M.J.; Atkin, S.L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999, 59, 5421-5424.
68. Speirs, V.; Carder, P.J.; Lane, S.; Dodwell, D.; Lansdown, M.R.; Hanby, A.M. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol. 2004, 5, 174-181.
69. Speirs, V.; Parkes, A.T.; Kerin, M.J.; Walton, D.S.; Carleton, P.J.; Fox, J.N.; Atkin, S.L. Coexpression of Estrogen Receptor (alpha) and {beta}: Poor Prognostic Factors in Human Breast Cancer? Cancer Res. 1999, 59, 525-528.
70. Paige, L.A.; Christensen, D.J.; Gron, H.; Norris, J.D.; Gottlin, E.B.; Padilla, K.M.; Chang, C.-y.; Ballas, L.M.; Hamilton, P.T.; McDonnell, D.P.; Fowlkes, D.M. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. USA 1999, 96, 3999-4004.
71. S. Katzenellenbogen, B.A Katzenellenbogen, J. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000, 2, 335-344.
72. Bardin, A.; Boulle, N.; Lazennec, G.; Vignon, F.; Pujol, P. Loss of ER {beta} expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 2004, 11, 537-551.
73. Kuiper, G.G.; Lemmmen, J.G.; Carlsson, B.; Cotton, J.C.; Safe, S.H.; van der Saag, P.T.; van der Burg, B.; Gustafsson, J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139, 4252-4263.
74. Mueller, S.O.; Katzenellenbogen, J.A.; Korach, K.S. Endogenous estrogen receptor beta is transcriptionally active in primary ovarian cells from estrogen receptor knockout mice. Steroids 2004, 69, 681-686.
75. Jordan, V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004, 5, 207-213.
76. Shang, Y.; Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295, 2465-2468.
77. O'Regan, R.M.; Cisneros, A.; England, G.M.; MacGregor, J.I.; Muenzner, H.D.; Assikis, V.J.; Bilimoria, M.M.; Piette, M.; Dragan, Y.P.; Pitot, H.C.; Chatterton, R.; Jordan, V.C. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 1998, 90, 1552-1558.
78. Grese, T.A.; Sluka, J.P.; Bryant, H.U.; Cullinan, G.J.; Glasebrook, A.L.; Jones, C.D.; Matsumoto, K.; Palkowitz, A.D.; Sato, M.; Termine, J.D.; Winter, M.A.; Yang, N.N.; Dodge, J.A. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. USA 1997, 94, 14105-14110.
79. Fornander, T.; Rutqvist, L.E.; Cedermark, B.; Glas, U.; Mattsson, A.; Silfversward, C.; Skoog, L.; Somell, A.; Theve, T.; Wilking, N. et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989, 1, 117-120.
80. Gottardis, M.M.; Robinson, S.P.; Satyaswaroop, P.G.; Jordan, V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988, 48, 812-815.
81. Jordan, V.C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2003, 2, 205-213.
82. Harper, M.J.; Walpole, A.L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 1967, 13, 101-1199
83. Senkus-Konefka, E.; Konefka, T.; Jassem, J. The effects of tamoxifen on the female genital tract. Cancer Treat. Rev. 2004, 30, 291-301.
84. Kim, S.Y.; Suzuki, N.; Laxmi, Y.R.; Shibutani, S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev. 2004, 36, 199-218.
85. Strasser-Weippl, K.; Goss, P.E. Advances in adjuvant hormonal therapy for postmenopausal women. J. Clin. Oncol. 2005, 23, 1751-1759.
86. Cuzick, J.; Powles, T.; Veronesi, U.; Forbes, J.; Edwards, R.; Ashley, S.; Boyle, P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361, 296-300.
87. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365, 1687-1717.
88. Jordan, V.C.; Collins, M.M.; Rowsby, L.; Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol 1977, 75, 305-316.
89. Katzenellenbogen, J.A.; Carlson, K.E.; Katzenellenbogen, B.S. Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J. Steroid Biochem. 1985, 22, 589-596.
90. Murphy, C.S.; Langan-Fabey, S.M.; McCague, R.; Jordan, V.C. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol. Pharmacol. 1990, 38, 737-743.
91. Jacolot, F.; Simon, I.; Dreano, Y.; Beaune, P.; Riche, C.; Berthou, F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 1991, 41, 1911-1919.
92. Lim, Y.C.; Desta, Z.; Flockhart, D.A.Skaar, T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 2005, 55, 471-478.
93. Johnson, M.D.; Zuo, H.; Lee, K.H.; Trebley, J.P.; Rae, J.M.; Weatherman, R.V.; Desta, Z.; Flockhart, D.A.; Skaar, T.C. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel activee metabolite of tamoxifen. Breast Cancer Res. Treat. 2004, 85, 151-159.
94. Jordan, V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 2003, 46, 883-908.
95. Shiau, A.K.; Barstad, D.; Loria, P.M.; Cheng, L.; Kushner, P.J.; Agard, D.A.; Greene, G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
96. McInerney, E.M. Katzenellenbogen, B.S. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J. Biol. Chem. 1996, 271, 24172-24178.
97. Metzger, D.; Ali, S.; Bornert, J.M. Chambon, P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J. Biol. Chem. 1995, 270, 9535-9542.
98. Gallo, M.A.; Kaufman, D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin. Oncol. 1997, 24, S1-71-S71-80.
99. Stearns, V.; Johnson, M.D.; Rae, J.M.; Morocho, A.; Novielli, A.; Bhargava, P.; Hayes, D.F.; Desta, Z.; Flockhart D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003, 95, 1758-1764.
100. Cranney, A.; Tugwell, P.; Zytaruk, N.; Robinson, V.; Weaver, B.; Adachi, J.; Wells, G.; Shea, B.; Guyatt, G. IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis. Endocr. Rev 2002, 23, 524-528.
101. Cummings, S.R.; Eckert, S.; Krueger, K.A.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M.; Lippman, M.E.; Black, D.; Glusman, J.E.; Costa, A.; Jordan, V.C. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial. JAMA 1999, 281, 2189-2197.
102. Martino, S.; Cauley, J.A.; Barrett-Connor, E.; Powles, T.J.; Mershon, J.; Disch, D.; Secrest, R.J.; Cummings, S.R. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. 2004, 96, 1751-1761.
103. Barrett-Connor, E.; Cox, D.A.; Anderson, P.W. The Potential of SERMs for Reducing the Risk of Coronary Heart Disease. Trends Endocrinol. Metabol. 1999, 10, 320-325.
104. Wenger, N.K.; Barrett-Connor, E.; Collins, P.; Grady, D.; Kornitzer, M.; Mosca, L.; Sashegyi, A.; Baygani, S.K.; Anderson, P.W.; Moscarelli, E. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am. J. Cardiol. 2002, 90, 1204-1210.
105. Mosca, L.; Barrett-Connor, E.; Wenger, N.K.; Collins, P.; Grady, D.; Kornitzer, M.; Moscarelli, E.; Paul, S.; Wright, T.J.; Helterbrand, J.D.; Anderson, P.W. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. 2001, 88, 392-395.
106. International Breast Cancer Study Group Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann. Oncol. 2004, 15, 1749-1759.
107. Kusama, M.; Miyauchi, K.; Aoyama, H.; Sano, M.; Kimura, M.; Mitsuyama, S.; Komaki, K.; Doihara, H. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids. Breast Cancer Res. Treat. 2004, 88, 1-8.
108. Buzdar, A.; Hayes, D.; El-Khoudary, A.; Yan, S.; LÃ, nning, P.; Lichinitser, M.; Gopal, R.; Falkson, G.; Pritchard, K.; Lipton, A.; Wolter, K.; Lee, A.; Fly, K.; Chew, R.; Alderdice, M.; Burke, K.; Eisenberg, P. Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Res. Treat. 2002, 73, 161-175.
109. Willson, T.M.; Henke, B.R.; Momtahen, T.M.; Charifson, P.S.; Batchelor, K.W.; Lubahn, D.B.; Moore, L.B.; Oliver, B.B.; Sauls, H.R.; Triantafillou, J.A. et al. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J. Med. Chem. 1994, 37, 1550-1552.
110. Willson, T.M.; Norris, J.D.; Wagner, B.L.; Asplin, I.; Baer, P.; Brown, H.R.; Jones, S.A.; Henke, B.; Sauls, H.; Wolfe, S.; Morris, D.C.; McDonnell, D.P. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 1997, 138, 3901-3911.
111. Connor, C.E.; Norris, J.D.; Broadwater, G.; Willson, T.M.; Gottardis, M.M.; Dewhirst, M.W.; McDonnell, D.P. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 2001, 61, 2917-2922.
112. Dardes, R.C.; O'Regan, R.M.; Gajdos, C.; Robinson, S.P.; Bentrem, D.; De Los Reyes, A.; Jordan, V.C. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin. Cancer Res. 2002, 8, 1995-2001.
113. Bentrem, D.; Dardes, R.; Liu, H.; MacGregor-Schafer, J.; Zapf, J.; Jordan, V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 2001, 142, 838-846.
114. Wu, Y.L.; Yang, X.; Ren, Z.; McDonnell, D.P.; Norris, J.D.; Willson, T.M.; Greene, G.L. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol. Cell. 2005, 18, 413-424.
115. Arpino, G.; Nair Krishnan, M.; Doval Dinesh, C.; Bardou, V.J.; Clark, G.M.; Elledge, R.M. Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. Ann. Oncol. 2003, 14, 233-241.
116. Vogelvang, T.E.; van der Mooren, M. J.; Mijatovic, V.; Kenemans, P. Emerging selective estrogen modulators: special focus on effects on coronary heart disease in postmenopausal women. Drugs 2006, 66, 191-221.
117. Buzdar, A.; O'Shaughnessy, J.A.; Booser, D.J.; Pippen, J.E. Jr.; Jones, S.E.; Munster, P.N.; Peterson, P.; Melemed, A.S.; Winer, E.; Hudis, C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2003, 21, 1007-1014.
118. Baselga, J.; Llombart-Cussac, A.; Bellet, M.; Guilillem-Porta, V.; Enas, N.; Krejcy, K.; Carrasco, E.; Kayitalire, L.; Kuta, M.; Lluch, A.; Vodvarka, P.; Kerbrat, P.; Namer, M.; Petruzelka, L. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann. Oncol. 2003, 14, 1383-1390.
119. McMeekin, D.S.; Gordon, A.; Fowler, J.; Melemed, A.; Buller, R.; Burke, T.; Bloss, J.; Sabbatini, P. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol. Oncol. 2003, 90, 64-69.
120. Fabian, C.J.; Kimler, B.F.; Anderson, J.; Tawfik, O.W.; Mayo, M.S.; Burak, W.E. Jr.; O'Shaughnessy, J.A.; Albain, K.S.; Hyams, D.M.; Budd, G.T.; Ganz, P.A.; Sauter, E.R.; Beenken, S.W.; Grizzle, W.E.; Fruehauf, J.P.; Arneson, D.W.; Bacus, J.W.; Lagios, M.D.; Johnson, K.A.; Browne, D. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clin. Cancer Res. 2004, 10, 5403-5417.
121. Sporn, M.B. Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer: Commentary re C. J. Fabian et al. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clin Cancer Res 2004;10:5403-17.
122. Sporn, M.B. Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer: Commentary re C. J. Fabian et al. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clin. Cancer Res. 2004, 10, 5313-5315.
123. Renehan, A.G.; Zwahlen, M.; Minder, C.; O'Dwyer, S.T.; Shalet, S.M.; Egger, M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363, 1346-1353.
124. Komm, B.S.; Kharode, Y.P.; Bodine, P.V.; Harris, H.A.; Miller, C.P.; Lyttle, C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005, 146, 3999-4008.
125. Schafer, J.I.; Liu, H.; Tonetti, D.A.; Jordan, V.C. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res. 1999, 59, 4308-4313.
126. Gutman, M.; Couillard, S.; Roy, J.; Labrie, F.; Candas, B.; Labrie, C. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Inter. J. Cancer 2002, 99, 273-278.
127. Labrie, F.; Champagne, P.; Labrie, C.; Roy, J.; Laverdiere, J.; Provencher, L.; Potvin, M.; Drolet, Y.; Pollak, M.; Panasci, L.; L'Esperance, B.; Dufresne, J.; Latreille, J.; Robert, J.; Samson, B.; Jolivet, J.; Yelle, L.; Cusan, L.; Diamond, P.; Candas, B. Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer. J. Clin. Oncol. 2004, 22, 864-871.
128. Smith, I. Breast cancer: Adjuvant treatment for early breast cancer. Ann. Oncol. 2005, 16, ii 182-187.
129. Fisher, B.; Dignam, J.; Bryant, J.; Wolmark, N. Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. J. Natl. Cancer Inst. 2001, 93, 684-690.
130. Evans, C.T.; Ledesma, D.B.; Schulz, T.Z.; Simpson, E.R.; Mendelson, C.R. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proc. Natl. Acad. Sci. USA 1986, 83, 6387-6391.
131. Smith, I.E.; Dowsett, M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003, 348, 2431-2442.
132. Nelson, L.R.; Bulun, S.E. Estrogen production and action. J. Am. Acad. Dermatol. 2001, 45, S116-S124.
133. Klein, K.O.; Demers, L.M.; Santner, S.J.; Baron, J.; Cutler, G.B. Jr.; Santen, R.J. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J. Clin. Endocrinol. Metab. 1995, 80, 2658-2660.
134. Mouridsen, H.; Gershanovich, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H.P.; Jaenicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P.P.; Salminen, E.; Snyder, R.; Chaudri-Ross, H.; Lang, R.; Wyld, P.; Bhatnagar, A. Phase III study of letrozole versus tamoxifen as firstline therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2003, 21, 2101-2109.
135. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Pater, J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 2005, 97, 1262-1271.
136. Bonneterre, J.; Thurlimann, B.; Robertson, J.F.R.; Krzakowski, M.; Mauriac, L.; Koralewski, P.; Vergote, I.; Webster, A.; Steinberg, M.; von Euler, M. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J. Clin. Oncol. 2000, 18, 3748-3757.
137. Boccardo, F.; Rubagotti, A.; Puntoni, M.; Guglielmini, P.; Amoroso, D.; Fini, A.; Paladini, G.; Mesiti, M.; Romeo, D.; Rinaldini, M.; Scali, S.; Porpiglia, M.; Benedetto, C.; Restuccia, N.; Buzzi, F.; Franchi, R.; Massidda, B.; Distante, V.; Amadori, D.; Sismondi, P. Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol. 2005, 23, 5138-5147.
138. Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud, T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359, 2131-2139.
139. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
140. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351, 1451-1467.
141. Dowsett, M.; Cuzick, J.; Wale, C.; Howell, T.; Houghton, J.; Baum, M. Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study. J. Clin. Oncol. 2005, 23, 7512-7517.
142. Lonning, P.E. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res. Treat. 1998, 49 Suppl 1, S45-52; discussion S73-47.
143. Sainsbury, R. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br. J. Cancer 2004, 90, 1733-1739.
144. Geisler, J.; Lonning, P.E. Aromatase inhibition: translation into a successful therapeutic approach. Clin. Cancer Res. 2005, 11, 2809-2821.
145. Paridaens, R.; Therasse, P.; Dirix, L.; Beex, L.; Piccart, M.; Cameron, D.; Cufer, T.; Roozendaal, K.; Nooij, M.; Mattiacci, M.-R. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen M in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. J. Clin. Oncol. (Meeting Abstracts). 2004, 22, 515.
146. Coombes, R.C.; Hall, E.; Gibson, L.J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S.E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A.S.; Bajetta, E.; Dodwell, D.; Coleman, R.E.; Fallowfield, L.J.; Mickiewicz, E.; Andersen, J.; Lonning, P.E.; Cocconi, G.; Stewart, A.; Stuart, N.; Snowdon, C.F.; Carpentieri, M.; Massimini, G.; Bliss, J.M. the Intergroup Exemestane Study A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal. Women with Primary Breast Cancer. N. Engl. J. Med. 2004, 350, 1081-1092.
147. ATAC Trialist, G. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 year's' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
148. Lonning, P.E.; Geisler, J.; Krag, L.E.; Erikstein, B.; Bremnes, Y.; Hagen, A.I.; Schlichting, E.; Lien, E.A.; ofjord, E.S.; Paolini, J.; Polli, A.; Massimini, G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected e arly breast cancer. J. Clin. Oncol. 2005, 23, 5126-5137.
149. Del Mastro, L.; Venturini, M. ATAC trial update. Lancet 365, 1225-1225.
150. Dauvois, S.; White, R.; Parker, M. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106, 1377-1388.
151. Carlson, R.W. The history and mechanism of action of fulvestrant. Clin. Breast Cancer 2005, 6 Suppl 1, S5-8.
152. Howell, A.; Robertson, J.F.; Quaresma Albano, J.; Aschermannova, A.; Mauriac, L.; Kleeberg, U.R.; Vergote, I.; Erikstein, B.; Webster, A.; Morris, C. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20, 3396-3403.
153. Osborne, C.K.; Pippen, J.; Jones, S.E.; Parker, L.M.; Ellis, M.; Come, S.; Gertler, S.Z.; May, J.T.; Burton, G.; Dimery, I.; Webster, A.; Morris, C.; Elledge, R.; Buzdar, A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002, 20, 3386-3395.
154. Howell, A.; Robertson, J.F.R.; Abram, P.; Lichinitser, M.R.; Elledge, R.; Bajetta, E.; Watanabe, T.; Morris, C.; Webster, A.; Dimery, I.; Osborne, C.K. Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial. J. Clin. Oncol. 2004, 22, 1605-1613.
155. Robertson, J.F.; Harrison, M. Fulvestrant: pharmacokinetics and pharmacology. Br. J. Cancer 2004, 90 Suppl 1, S7-10.
156. Gradishar, W.J.; Sahmoud, T. Current and future perspectives on fulvestrant. Clin. Breast Cancer. 2005, 6 Suppl 1, S23-29.
157. Hoffmann, J.; Bohlmann, R.; Heinrich, N.; Hofmeister, H.; Kroll, J.; Kunzer, H.; Lichtner, R.B.; Nishino, Y.; Parczyk, K.; Sauer, G.; Gieschen, H.; Ulbrich, H.F.; Schneider, M.R. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J. Natl. Cancer Inst. 2004, 96, 210-218.
158. Van de Velde, P.; Nique, F.; Bouchoux, F.; Bremaud, J.; Hameau, M.C.; Lucas, D.; Moratille, C.; Viet, S.; Philibert, D.; Teutsch, G. RU 58, 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J. Steroid Biochem. Mol. Biol. 1994, 48, 187-196.
159. Van de Velde, P.; Nique, F.; Planchon, P.; Prevost, G.; Bremaud, J.; Hameau, M.C.; Magnien, V.; Philibert; D.; Teutsch, G. RU 58668: further in vitro and in vivo pharmacological data related to its antimmoral activity. J. Steroid Biochem. Mol. Biol. 1996, 59, 449-457.
160. El Khissiin, A.Leclercq, G. Implication of proteasome in estrogen receptor degradation. FEBS Lett. 1999, 448, 160-166.
161. Marsaud, V.; Gougelet, A.; Maillard, S.Renoir, J.M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 2003, 17, 2013-2027.
162. Yamamoto, Y.; Wada, O.; Takada, I.; Yogiashi, Y.; Shibata, J.; Yanagisawa, J.; Kitazato, K. Kato, S. Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand. Biochem. Biophys. Res. Commun. 2003, 312, 656-662.
163. Wolf, D.M.; Jordan, V.C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 1994, 31, 129-138.
164. Yamamoto, Y.; Shibata, J.; Yonekura, K.; Sato, K.; Hashimoto, A.; Aoyagi, Y.; Wierzba, K.; Yano, S.; Asao, T.; Buzdar, A.U.; Terada, T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin. Cancer Res. 2005, 11, 315-322.
165. Blakely, L.J.; Buzdar, A.; Chang, H.Y.; Frye, D.; Theriault, R.; Valero, V.; Rivera, E.; Booser, D.; Kuritani, J.; Tsuda, M. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin. Cancer Res. 2004, 10, 5425-5431.
166. Buzdar, A.U. TAS-108: A Novel Steroidal Antiestrogen. Clin. Cancer Res. 2005, 11, 906s-908.
167. Ree, A.H.; Landmark, B.F.; Eskild, W.; Levy, F.O.; Lahooti, H.; Jahnsen, T.; Aakvaag, A.; Hansson, V. Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels. Endocrinology, 1989, 124, 2577-2583.
168. Maass, H.; Jonat, W.; Stolzenbach, G.Trams, G. The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer. Cancer 1980, 46, 2835-2837.
169. Tonetti, D.A.; Jordan, V.C. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J. Steroid Biochem. Mol. Biol. 1997, 62, 119-128.
170. Wolf, D.M.; Langan-Fahey, S.M.; Parker, C.J.; McCague, R.; Jordan, V.C. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J. Natl. Cancer Inst. 1993, 85, 806-812.
171. Osborne, C.K.; Fuqua, S.A. Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat. 1994, 32, 49-55.
172. Tonetti, D.A.; Jordan, V.C. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 1995, 6, 498-507.
173. Zhang, Q.X; Borg, A.; Wolf, D.M.; Oesterreich, S.; Fuqua, S.A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997, 57, 1244-1249.
174. Kamik, P.S.; Kulkarni, S.; Liu, X.P.; Budd, G.T.; Bukowski, R.M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994, 54, 349-353.
175. Robertson, J.F. Oestrogen receptor: a stable phenotype in breast cancer. Br. J. Cancer 1996, 73, 5-12.
176. Gottardis, M.M.; Jordan, V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988, 48, 5183-5187.
177. Gottardis, M.M.; Jiang, S.Y.; Jeng, M.H.; Jordan, V.C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989, 49, 4090-4093.
178. Wolf, D.M.; Jordan, V.C. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat. 1994, 31, 117-127.
179. Yao, K.; Bentrem, D.J.; England, G.; Lee, E.-S.; Schafer, J.I.M.; Jordan, V.C.; O'Regan, R.M. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 2000, 6, 2028-2036.
180. Osipo, C.; Gajdos, C.; Liu, H.; Chen, B.; Jordan, V.C. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J. Natl. Cancer Inst. 2003, 95, 1597-1608.
181. Osborne, C.K.; Coronado, E.B.; Robinson, J.P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol. 1987, 23, 1189-1196.
182. Osipo, C.; Gajdos, C.; Cheng, D.; Jordan, V.C. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J. Steroid Biochem. Mol. Biol. 2005, 93, 249-256.
183. Benz, C.C.; Scott, G.K.; Sarup, J.C.; Johnson, R.M.; Tripathy, D.; Coronado, E.; Shepard, H.M.; Osborne, C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 1993, 24, 85-95.
184. Shou, J.; Massarweh, S.; Osborne, C.K.; Wakeling, A.E.; Ali, S.; Weiss, H.; Schiff, R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 2004, 96, 926-935.
185. Howell, A.; Dodwell, D.J.; Anderson, H., Redford, J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol. 1992, 3, 611-617.
186. Dosik, M.; Kaulman, R. Raloxifene rebound regression. Cancer Invest. 2004, 22, 718-722.
187. Belani, C.P.; Pearl, P.; Whitley, N.O.; Aisner, J. Tamoxifen withdrawal response. Report of a case. Arch. Intern. Med. 1989, 149, 449-450.
188. Canney, P.A.; Griffiths, T.; Latief, T.N.; Priestman, T.J. Clinical significance of tamoxifen withdrawal response. Lancet 1987, 1, 36.
189. Gockerman, J.P.; Spremulli, E.N.; Raney, M.; Logan, T. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or - unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. Cancer Treat. Rep. 1986, 70, 1199-1203.
190. Stein, W., 3rd; Hortobagyi, G.N.; Blumenschein, G.R. Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J. Surg. Oncol. 1983, 22, 45-46.
191. Legault-Poisson, S.; Jolivet, J.; Poisson, R.; Beretta-Piccoli, M.; Band, P.R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep. 1979, 63, 1839-1841.
192. Osborne, C.K.; Coronado, E.; Allred, D.C.; Wiebe, V.; DeGregorio, M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans4-hydroxytamoxifen. J. Natl. Cancer Inst. 1991, 83, 1477-1482.
193. Gottardis, M.M.; Robinson, S.P.; Jordan, V.C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid Biochem. 1998, 30, 311-314.
194. Wolf, D.M.; Jordan, V.C. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 1993, 127, 23-33.
195. Yao, K.; Lee, E.S.; Bentrem, D.J.; England, G.; Schafer, J.I.; O'Regan, R.M.; Jordan, V.C. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 2000, 6, 2028-2036.
196. Liu, H.; Lee, E.S.; Gajdos, C.; Pearce, S.T.; Chen, B.; Osipo, C.; Loweth, J.; McKian, K.; De Los Reyes, A.; Wing, L.; Jordan, V.C. Apoptotic action of l7beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J. Natl. Cancer Inst. 2003, 95, 1586-1597.
197. Tonetti, D.A.; Chisamore, M.J.; Grdina, W.; Schutz, H.; Jordan, V.C. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br. J. Cancer 2000, 83, 782-791.
198. Chisamore, M.J.; Ahmed, Y.; Bentrem, D.J.; Jordan, V.C.Tonetti, D.A. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin. Cancer Res. 2001, 7, 3156-3165.
199. Pink, J.J.; Jiang, S.Y.; Fritsch, M.; Jordan, V.C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res. 1995, 55, 2583-2590.
200. Jeng, M.H.; Shupnik, M.A.; Bender, T.P.; Westin, E.H.; Bandyopadhyay, D.; Kumar, R.; Masamura, S.; Santen, R.J. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998, 139, 4164-4174.
201. Pink, J.J.; Bilimoria, M.M.; Assikis, J.; Jordan, V.C. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following Ariad et al. prolonged oestrogen deprivation. Br. J. Cancer 1996, 74, 1227-1236.
202. Brodie, A.; Jelovac, D.; Sabnis, G.; Long, B.; Macedo, L.; Goloubeva, O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J. Steroid Biochem. Mol. Biol. 2005, 95, 41-48.
203. Brodie, A.H.; Jelovac, D.; Long, B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem. Mol. Biol. 2003, 86, 283-288.
204. Song, R.X; McPherson, R.A.; Adam, L.; Bao, Y.; Shupnik, M.; Kumar, R.Santen, R.J. Linkage of rapid estrogen action to MAPK activation by ERalpha-She association and She pathway activation. Mol. Endocrinol. 2002, 16, 116-127.
205. Song, R.X; Mor, G.; Naftolin, F.; McPherson, R.A.; Song, J.; Zhang, Z.; Yue, W.; Wang, J.; Santen, R.J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J. Natl. Cancer Inst. 2001, 93, 1714-1723.
206. Lewis, J.S.; Osipo, C.; Meeke, K.; Jordan, V.C. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J. Steroid Biochem. Mol. Biol. 2005, 94, 131-141.
207. Lewis, J.S.; Meeke, K.; Osipo, C.; Ross, E.A.; Kidawi, N.; Li, T.; Bell, E.; Chandel, N.S.; Jordan, V.C. Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen Deprivation. J. Natl. Cancer Inst. 2005, 97, 1746-1759.
208. Cormier, E.; Wolf, M.; Jordan, V. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res. 1989, 49, 576-580.
209. Robinson, S.P.; Jordan, V. The Paracrine Stimulation of MCF-7 Cells by MDA-MB-231 Cells: Possible Role of Antiestrogen Failure. Eur. J. Cancer Clin. Oncol. 1999, 25, 493-497.
210. Levin, E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 2003, 17, 309-317.
211. Bardou, V.-J.; Arpino, G.; Elledge, R.M.; Osborne, C.K.Clark, G.M. Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. J. Clin. Oncol. 2003, 21, 1973-1979.
212. Arpino, G.; Weiss, H.; Lee, A.V.; Schiff, R.; De Placido, S.; Osborne, C.K.; Elledge, R.M. Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance. J. Natl. Cancer Inst. 2005, 97, 1254-1261.
213. Razandi, M.; Pedram, A.; Levin, E.R. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol. Endocrinol. 2000, 14, 1434-1447.
214. Pedram, A.; Razandi, M.; Aitkenhead, M.; Hughes, C.C.; Levin, E.R. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J. Biol. Chem. 2002, 277, 50768-50775.
215. Marquez, D.C.; Pietras, R.J. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001, 20, 5420-5430.
216. Razandi M.; Pedram, A.; Greene, G.L.; Levin, E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol 1999, 13, 307-319.
217. Santen, R.J.; Song, R.X; Zhang, Z.; Kumar, R.; Jeng, M.H.; Masamura, S.; Yue, W.; Berstein, L. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr. Relat. Cancer 2003, 10, 111-130.
218. Razandi, M.; Oh, P.; Pedram, A.; Schnitzer, J.; Levin, E.R. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol. Endocrinol. 2002, 16, 100-115.
219. Razandi, M.; Alton, G.; Pedram, A.; Ghonshani, S.; Webb, P.; Levin, E.R. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol. Cell Biol. 2003, 23, 1633-1646.
220. Razandi, M.; Pedram, A., Merchenthaler, I.; Greene, G.L.; Levin, E.R. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol. 2004, 18, 2854-2865.
221. Razandi, M.; Pedram, A.; Park, S.T.; Levin, E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 2003, 278, 2701-2712.
222. Yue, W.; Wang, J.P.; Conaway, M.; Masamura, S.; Li, Y.; Santen, R.J. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 2002, 143, 3221-3229.
223. Yue, W.; Wang, J.P.; Conaway, M.R.; Li, Y.; Santen, R.J. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J. Steroid Biochem. Mol. Biol. 2003, 86, 265-274.
224. Takimoto, G.S.; Graham, J.D.; Jackson, T.A.; Tung, L.; Powell, R.L.; Horwitz, L.D.; Horwitz, K.B. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J. Steroid Biochem. Mol. Biol. 1999, 69, 45-50.
225. Lavinsky, R.M.; Jepsen, K.; Heinzel, T.; Torchia, J.; Mullen, T.M.; Schiff, R.; Del-Rio, A.L.; Ricote, M.; Ngo, S.; Gemsch, J.; Hilsenbeck, S.G.; Osborne, C.K.; Glass, C.K.; Rosenfeld, M.G.; Rose, D.W. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA 1998, 95, 2920-2925.
226. Smith., Nawaz, Z.; O'Malley, B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol 1997, 11, 657-666.
227. Jackson, T.A.; Richer, J.K.; Bain, D.L.; Takimoto, G.S.; Tung, L.; Horwitz, K.B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 1997, 11, 693-705.
228. Girault, I.; Lerebours, F.; Amarir, S.; Tozlu, S.; Tubiana-Hulin, M.; Lidereau, R.; Bieche, I. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCORI expression is predictive of the response to tamoxifen. Clin. Cancer Res. 2003, 9, 1259-1266.